Patrick J. Haley - Feb 6, 2023 Form 4 Insider Report for EXELIXIS, INC. (EXEL)

Role
EVP, Commercial
Signature
/s/ Nina Ayer, Attorney in Fact
Stock symbol
EXEL
Transactions as of
Feb 6, 2023
Transactions value $
-$329,250
Form type
4
Date filed
2/8/2023, 07:17 PM
Previous filing
Nov 17, 2022
Next filing
Feb 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EXEL Common Stock Options Exercise $105K +25K +9.83% $4.20* 279K Feb 6, 2023 Direct F1
transaction EXEL Common Stock Sale -$434K -25K -8.95% $17.37 254K Feb 6, 2023 Direct F2, F3
holding EXEL Common Stock 23.5K Feb 6, 2023 By spouse
holding EXEL Common Stock 10.6K Feb 6, 2023 By 401(k) F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EXEL Option (right to buy) Options Exercise $0 -25K -100% $0.00* 0 Feb 6, 2023 Common Stock 25K $4.20 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 151,866 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
F2 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 1, 2022.
F3 Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.30 to $17.50. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
F4 Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of February 3, 2023.
F5 The option, representing the right to purchase a total of 25,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 11, 2020.